Application of 18F-DOPA PET/CT in pediatric neuroblastoma: a prospective, single center, open label clinical study

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000035995

Enrollment

Unknown

Registered

2020-08-21

Start date

2020-10-01

Completion date

Unknown

Last updated

2020-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuroblastoma

Interventions

Gold Standard:Positive findings are to be confirmed by histopathology/biopsy, imaging and clinical follow-up.

Index test:18F-DOPA PET/CT scan

Eligibility

Sex/Gender

All

Age

1 Years to 18 Years

Inclusion criteria

Inclusion criteria: 1. Aged >= 1 year and <18 year; 2. Histopathologically proven neuroblastoma; 3. 24h VMA or HVA, NSE, bone marrow biopsy in 2 weeks; 4. Ability to understand a written informed consent document and the willingness to sign it.

Exclusion criteria

Exclusion criteria: 1. A history of other active malignancy; 2. Allergy to 18F-DOPA; 3. Unable to lie flat, still or tolerate a PET scan; 4. Severe CVD, infection, uncontrollable disease, pregnancy or breastfeeding.

Design outcomes

Secondary

Measure	Time frame
Positive predictive value;	—

Primary

Measure	Time frame
Sensitivity;	—

Countries

China

Contacts

Public ContactSuyun Chen

Xinhua Hospital, Shanghai Jiaotong University School of Medicine

nuyus@outlook.com+86 18521301390

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026